Publicacions en què col·labora amb Gloria González Aseguinolaza (29)

2023

  1. Cardiac Progenitor Cell Exosomal miR-935 Protects against Oxidative Stress

    Cells, Vol. 12, Núm. 18

  2. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

2021

  1. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

2020

  1. Effect of heart ischemia and administration route on biodistribution and transduction efficiency of AAV9 vectors

    Journal of Tissue Engineering and Regenerative Medicine, Vol. 14, Núm. 1, pp. 123-134

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1

2016

  1. Generation and characterization of human iPSC lines derived from a Primary Hyperoxaluria Type I patient with p.I244T mutation

    Stem Cell Research, Vol. 16, Núm. 1, pp. 116-119

  2. Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function

    OncoImmunology, Vol. 5, Núm. 8

2015

  1. Chronic exposure to IFNα drives medullar lymphopoiesis towards t-cell differentiation in mice

    Haematologica, Vol. 100, Núm. 8, pp. 1014-1022

  2. Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I

    Journal of Hepatology, Vol. 63, Núm. 2, pp. 329-336

2013

  1. Cytokines for the treatment of gastrointestinal cancers: Clinical experience and new perspectives

    Expert Opinion on Investigational Drugs, Vol. 22, Núm. 7, pp. 827-841

2011

  1. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties

    Hepatology, Vol. 53, Núm. 6, pp. 1864-1873

  2. Characterization of woodchuck apolipoprotein A-I: A new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model

    Journal of Medical Virology, Vol. 83, Núm. 7, pp. 1221-1229

  3. Development of a liver-specific tet-on inducible system for AAV vectors and its application in the treatment of liver cancer

    Molecular Therapy, Vol. 19, Núm. 7, pp. 1245-1253

  4. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice

    Gut, Vol. 60, Núm. 3, pp. 341-349

  5. Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of Interleukin-12

    Journal of Virology

2010

  1. Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis

    Cancer Gene Therapy, Vol. 17, Núm. 1, pp. 20-27

  2. Gene therapy: A pharmacokinetic/pharmacodynamic modelling overview

    Pharmaceutical Research, Vol. 27, Núm. 8, pp. 1487-1497

2009

  1. Advances in interleukin-12 gene therapy for acquired liver diseases

    Current Gene Therapy, Vol. 9, Núm. 2, pp. 62-71

  2. Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders

    Human Gene Therapy, Vol. 20, Núm. 8, pp. 908-917

  3. Production of recombinant woodchuck IFNα and development of monoclonal antibodies

    Journal of Interferon and Cytokine Research, Vol. 29, Núm. 2, pp. 75-81